The Claim

Combination therapy using photodynamic therapy and ranibizumab significantly improves best-corrected visual acuity by a mean difference of 0.07 logMAR units and reduces central subfield thickness by 42.09 micrometers compared to ranibizumab monotherapy in treatment-naïve patients with polypoidal choroidal vasculopathy, while also achieving complete polyp regression in up to 77.8% of cases and reducing the number of required anti-VEGF injections.

Source: Comparative efficacy of photodynamic therapy (PDT), ranibizumab, aflibercept monotherapy, and combination therapies for polypoidal choroidal vasculopathy: a network meta-analysis of randomized controlled trials

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
60score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

In treatment-naïve patients with polypoidal choroidal vasculopathy, combining photodynamic therapy with ranibizumab results in a measurable improvement in visual acuity, a reduction in retinal thickness, complete regression of polyps in up to 77.8% of cases, and fewer anti-VEGF injections compared to ranibizumab alone.

See the scientific wording

Combination therapy using photodynamic therapy and ranibizumab significantly improves best-corrected visual acuity by a mean difference of 0.07 logMAR units and reduces central subfield thickness by 42.09 micrometers compared to ranibizumab monotherapy in treatment-naïve patients with polypoidal choroidal vasculopathy, while also achieving complete polyp regression in up to 77.8% of cases and reducing the number of required anti-VEGF injections.

Why this might work

The light treatment destroys abnormal blood vessels in the eye, while the injection blocks a protein that causes fluid leakage and new vessel growth. Together, they shut down the leaky vessels, dry out the swollen retina, and prevent new ones from forming, leading to better vision and fewer treatments needed.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Comparative efficacy of photodynamic therapy (PDT), ranibizumab, aflibercept monotherapy, and combination therapies for polypoidal choroidal vasculopathy: a network meta-analysis of randomized controlled trials

    For people with this eye condition, combining a special light treatment with eye injections works better than injections alone—it improves vision more, reduces fluid in the eye, makes abnormal blood vessels disappear more often, and means fewer injections over time.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.